Silver Book Fact

If the progression of Parkinson’s disease were slowed by 50%, there would be a 35% reduction in excess costs.

Johnson, SJ, MD Diener, A Kaltenboeck, HG Binbaum, and AD Siderowf. An Economic Model of Parkinson’s Disease: Implications for slowing progression in the United States. Mov Disord. 2013; http://www.ncbi.nlm.nih.gov/pubmed/23404374

Reference

Title
An Economic Model of Parkinson’s Disease: Implications for slowing progression in the United States
Publication
Mov Disord
Publication Date
2013
Authors
Johnson, SJ, MD Diener, A Kaltenboeck, HG Binbaum, and AD Siderowf
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, 42 medicines are currently in development for Alzheimer’s disease.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years were introduced in 2015, by 2050 the total reduction in cost of care for people…  
  • If the progression of Parkinson’s disease were slowed by 50%, there would be a 35% reduction in excess costs.  
  • One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.  
  • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development uses normal human cells to enhance brain levels of dopamine, the neurotransmitter deficient…